S&P 500   5,061.82
DOW   37,735.11
QQQ   431.06
5 Small-Cap Energy Stocks Surged in Price and Volume on Friday
Novo Nordisk Arms Wegovy to Be a Triple Threat
Vital Farms Rides the Pasture-Raised Egg Trend to the Bank
3 Energy Plays for Cash Flow: Buy 1 or Buy Them All
M&T Bank, Goldman Sachs rise; Salesforce, Tesla fall, Monday, 4/15/2024
When Will the Next Bull Market Be?
Global smartphone shipments climb nearly 8% in 1st quarter as Samsung retakes the lead
S&P 500   5,061.82
DOW   37,735.11
QQQ   431.06
5 Small-Cap Energy Stocks Surged in Price and Volume on Friday
Novo Nordisk Arms Wegovy to Be a Triple Threat
Vital Farms Rides the Pasture-Raised Egg Trend to the Bank
3 Energy Plays for Cash Flow: Buy 1 or Buy Them All
M&T Bank, Goldman Sachs rise; Salesforce, Tesla fall, Monday, 4/15/2024
When Will the Next Bull Market Be?
Global smartphone shipments climb nearly 8% in 1st quarter as Samsung retakes the lead
S&P 500   5,061.82
DOW   37,735.11
QQQ   431.06
5 Small-Cap Energy Stocks Surged in Price and Volume on Friday
Novo Nordisk Arms Wegovy to Be a Triple Threat
Vital Farms Rides the Pasture-Raised Egg Trend to the Bank
3 Energy Plays for Cash Flow: Buy 1 or Buy Them All
M&T Bank, Goldman Sachs rise; Salesforce, Tesla fall, Monday, 4/15/2024
When Will the Next Bull Market Be?
Global smartphone shipments climb nearly 8% in 1st quarter as Samsung retakes the lead
S&P 500   5,061.82
DOW   37,735.11
QQQ   431.06
5 Small-Cap Energy Stocks Surged in Price and Volume on Friday
Novo Nordisk Arms Wegovy to Be a Triple Threat
Vital Farms Rides the Pasture-Raised Egg Trend to the Bank
3 Energy Plays for Cash Flow: Buy 1 or Buy Them All
M&T Bank, Goldman Sachs rise; Salesforce, Tesla fall, Monday, 4/15/2024
When Will the Next Bull Market Be?
Global smartphone shipments climb nearly 8% in 1st quarter as Samsung retakes the lead
NASDAQ:URGN

UroGen Pharma (URGN) Stock Price, News & Analysis

$15.10
0.00 (0.00%)
(As of 04/15/2024 ET)
Today's Range
$14.21
$15.43
50-Day Range
$12.95
$19.33
52-Week Range
$8.69
$24.13
Volume
661,672 shs
Average Volume
413,298 shs
Market Capitalization
$354.10 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$46.67

UroGen Pharma MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
209.1% Upside
$46.67 Price Target
Short Interest
Bearish
17.86% of Shares Sold Short
Dividend Strength
N/A
Sustainability
-1.33
Upright™ Environmental Score
News Sentiment
1.08mentions of UroGen Pharma in the last 14 days
Based on 3 Articles This Week
Insider Trading
Selling Shares
$306,829 Sold Last Quarter
Proj. Earnings Growth
Growing
From ($3.59) to ($1.75) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

4.20 out of 5 stars

Medical Sector

155th out of 929 stocks

Pharmaceutical Preparations Industry

58th out of 422 stocks

URGN stock logo

About UroGen Pharma Stock (NASDAQ:URGN)

UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization of solutions for urothelial and specialty cancers. It offers RTGel, a novel proprietary polymeric biocompatible, reverse thermal gelation hydrogel technology to improve therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution. The company's lead product candidate is UGN-102 for the treatment of several forms of non-muscle invasive urothelial cancer that include low-grade upper tract urothelial cancer and low-grade intermediate risk non-muscle invasive bladder cancer (NMIBC). It is also developing UGN-301 for the treatment of high-grade NMIBC. The company has license agreement with Agenus Inc. to develop, make, use, sell, import, and commercialize products of Agenus for the treatment of cancers of the urinary tract via intravesical delivery; strategic research collaboration agreement with MD Anderson focusing on the sequential use of UGN-201 and UGN-301 for the treatment of NMIBC; and licensing and supply agreement with medac Gesellschaft für klinische Spezialpräparate m.b.H. to develop UGN-103 in low-grade intermediate risk NMIBC and UGN-104 in low-grade upper tract urothelial carcinoma. UroGen Pharma Ltd. was incorporated in 2004 and is based in Princeton, New Jersey.

URGN Stock Price History

URGN Stock News Headlines

REVEALED: Elon Musk’s Secret A.I. Facility?
I recently shot this video outside what could be Elon Musk’s biggest secret. What’s happening inside these walls is so important that our government has declared it a matter of national security.
UroGen: All Eyes On UGN-102
REVEALED: Elon Musk’s Secret A.I. Facility?
I recently shot this video outside what could be Elon Musk’s biggest secret. What’s happening inside these walls is so important that our government has declared it a matter of national security.
UroGen Pharma earnings preview: what to expect
3 Biotech Stocks Climbing the Ranks to Watch
URGN Mar 2024 22.500 call
URGN Mar 2024 17.500 call
URGN Mar 2024 10.000 put
UroGen Pharma Ltd URGN
UroGen Pharma Ltd (URGN)
See More Headlines
Receive URGN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for UroGen Pharma and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
3/14/2024
Today
4/16/2024
Next Earnings (Estimated)
5/09/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:URGN
Fax
N/A
Employees
198
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$46.67
High Stock Price Target
$54.00
Low Stock Price Target
$34.00
Potential Upside/Downside
+209.1%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
2 Analysts

Profitability

Net Income
$-102,240,000.00
Net Margins
-123.61%
Pretax Margin
-118.87%

Debt

Sales & Book Value

Annual Sales
$82.71 million
Book Value
($2.78) per share

Miscellaneous

Free Float
20,844,000
Market Cap
$354.16 million
Optionable
Optionable
Beta
1.07
(Almost) Everything You Need To Know About The EV Market Cover

Click the link below and we'll send you MarketBeat's guide to investing in electric vehicle technologies (EV) and which EV stocks show the most promise.

Get This Free Report

Key Executives


URGN Stock Analysis - Frequently Asked Questions

Should I buy or sell UroGen Pharma stock right now?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for UroGen Pharma in the last twelve months. There are currently 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" URGN shares.
View URGN analyst ratings
or view top-rated stocks.

What is UroGen Pharma's stock price target for 2024?

2 equities research analysts have issued 12-month price objectives for UroGen Pharma's stock. Their URGN share price targets range from $34.00 to $54.00. On average, they anticipate the company's stock price to reach $46.67 in the next year. This suggests a possible upside of 209.1% from the stock's current price.
View analysts price targets for URGN
or view top-rated stocks among Wall Street analysts.

How have URGN shares performed in 2024?

UroGen Pharma's stock was trading at $15.00 on January 1st, 2024. Since then, URGN shares have increased by 0.7% and is now trading at $15.10.
View the best growth stocks for 2024 here
.

When is UroGen Pharma's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, May 9th 2024.
View our URGN earnings forecast
.

How were UroGen Pharma's earnings last quarter?

UroGen Pharma Ltd. (NASDAQ:URGN) released its quarterly earnings data on Thursday, March, 14th. The company reported ($0.72) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.67) by $0.05. The firm earned $23.53 million during the quarter, compared to analyst estimates of $22.30 million.

What ETFs hold UroGen Pharma's stock?

ETFs with the largest weight of UroGen Pharma (NASDAQ:URGN) stock in their portfolio include ARK Israel Innovative Technology ETF (IZRL).Amplify BlueStar Israel Technology ETF (ITEQ).

What other stocks do shareholders of UroGen Pharma own?

Based on aggregate information from My MarketBeat watchlists, some companies that other UroGen Pharma investors own include Sorrento Therapeutics (SRNE), Micron Technology (MU), OPKO Health (OPK), TG Therapeutics (TGTX), VBI Vaccines (VBIV), Exelixis (EXEL), (KITE) (KITE), Syndax Pharmaceuticals (SNDX), AbbVie (ABBV) and Aytu BioPharma (AYTU).

When did UroGen Pharma IPO?

UroGen Pharma (URGN) raised $46 million in an IPO on Thursday, May 4th 2017. The company issued 3,500,000 shares at $12.00-$14.00 per share. Jefferies and Cowen and Company acted as the underwriters for the IPO and Raymond James and Oppenheimer were co-managers.

How do I buy shares of UroGen Pharma?

Shares of URGN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:URGN) was last updated on 4/16/2024 by MarketBeat.com Staff

From Our Partners